IT201900002155A1 - Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici - Google Patents

Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici

Info

Publication number
IT201900002155A1
IT201900002155A1 IT102019000002155A IT201900002155A IT201900002155A1 IT 201900002155 A1 IT201900002155 A1 IT 201900002155A1 IT 102019000002155 A IT102019000002155 A IT 102019000002155A IT 201900002155 A IT201900002155 A IT 201900002155A IT 201900002155 A1 IT201900002155 A1 IT 201900002155A1
Authority
IT
Italy
Prior art keywords
serpinb3
therapeutic agents
genetically modified
modified cells
extracellular vesicles
Prior art date
Application number
IT102019000002155A
Other languages
English (en)
Inventor
Patrizia Pontisso
Maurizio Muraca
Alessandra Biasiolo
Santina Quarta
Mariagrazia Ruvoletto
Gianmarco Villano
Original Assignee
Univ Degli Studi Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Padova filed Critical Univ Degli Studi Padova
Priority to IT102019000002155A priority Critical patent/IT201900002155A1/it
Priority to US17/430,739 priority patent/US12239667B2/en
Priority to EP20709715.5A priority patent/EP3923961A1/en
Priority to PCT/IB2020/051244 priority patent/WO2020165851A1/en
Publication of IT201900002155A1 publication Critical patent/IT201900002155A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
IT102019000002155A 2019-02-14 2019-02-14 Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici IT201900002155A1 (it)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT102019000002155A IT201900002155A1 (it) 2019-02-14 2019-02-14 Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici
US17/430,739 US12239667B2 (en) 2019-02-14 2020-02-14 Extracellular vesicles isolated from genetically modified cells over-expressing SERPINB3 for use in medicine
EP20709715.5A EP3923961A1 (en) 2019-02-14 2020-02-14 Extracellular vesicles isolated from genetically modified cells over-expressing serpinb3 for use in medicine
PCT/IB2020/051244 WO2020165851A1 (en) 2019-02-14 2020-02-14 Extracellular vesicles isolated from genetically modified cells over-expressing serpinb3 for use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000002155A IT201900002155A1 (it) 2019-02-14 2019-02-14 Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici

Publications (1)

Publication Number Publication Date
IT201900002155A1 true IT201900002155A1 (it) 2020-08-14

Family

ID=66589717

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000002155A IT201900002155A1 (it) 2019-02-14 2019-02-14 Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici

Country Status (4)

Country Link
US (1) US12239667B2 (it)
EP (1) EP3923961A1 (it)
IT (1) IT201900002155A1 (it)
WO (1) WO2020165851A1 (it)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014013258A1 (en) * 2012-07-19 2014-01-23 Reneuron Limited Stem cell microparticles
US20180220642A1 (en) * 2015-07-29 2018-08-09 Indiana University Research And Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2957217T3 (es) * 2015-12-08 2024-01-15 Umc Utrecht Holding Bv Marcadores de vesículas extracelulares para angina estable y angina inestable

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014013258A1 (en) * 2012-07-19 2014-01-23 Reneuron Limited Stem cell microparticles
US20180220642A1 (en) * 2015-07-29 2018-08-09 Indiana University Research And Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CANNITO STURATO CPATERNOSTRO CBIASIOLO ACOLOMBATTO SCAMBIERI THEFOURTH SVILLANO GFASOLATO SMUSSO T: "Hypoxya up-regola SerpinB3 through HIF-2a in human liver cancer cells", ONCOTARGET, vol. 6, 2015, pages 2206 - 2221
FOURTH SVIDALINO LTURATO CRUVOLETTO MCALABRESE FVALENT MCANNITO SFASSINA GWORD MGATTA A: "SerpinB3 induces epithelial-mesenchymal transition", J PATHOL, vol. 221, 2010, pages 343 - 356
G, TURATOVILLANO CFOURTH SRUVOLETTO MCISCATO FPATERNOSTRO CWORD MSEMERARO RALVARO DBERNARDI P: "Hepatic progenitor cells overexpress SerpinB3", BMC CELL BIOL, 2014
HALL JUSTIN ET AL: "Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma", CELLULAR AND MOLECULAR NEUROBIOLOGY, SPRINGER NEW YORK, US, vol. 36, no. 3, 26 March 2016 (2016-03-26), pages 417 - 427, XP035904161, ISSN: 0272-4340, [retrieved on 20160326], DOI: 10.1007/S10571-015-0309-0 *
JOSEPH M CATANZARO ET AL: "SerpinB3/B4: Mediators of Ras-driven inflammation and oncogenesis", CELL CYCLE, vol. 13, no. 20, 15 October 2014 (2014-10-15), US, pages 3155 - 3156, XP055629521, ISSN: 1538-4101, DOI: 10.4161/15384101.2014.969991 *
KOUREMBANAS S: "Exosomes: Vehicles of Intercellular Signaling, Biomarkers, and vectors of Cell Therapy", ANNU REV PHYSIOL, vol. 77, 2015, pages 13 - 27
MURACA MSMALL MFRANZIN CPTOLEMY AMJURGA MM, POZZOBON PERILONGO G: "diverging Concepts and Novel Perspectives in Regenerative Medicine", INT. J. MOL. SCI., vol. 18, no. 5, 2017, pages 1021
RUENN CHAI LAI ET AL: "Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome", INTERNATIONAL JOURNAL OF PROTEOMICS, vol. 91, no. 7, 1 January 2012 (2012-01-01), pages 2573 - 14, XP055155534, ISSN: 2090-2166, DOI: 10.1155/2012/971907 *
SCIACOVELLI CISCATO F, G, MVILLANO TURATO CBERNARDI PRASOLA APONTISSO P: "SerpinB3 protects from oidative damage by chemotherapeutics through inhibition of mithocondrial respratory complex I", ONCOTARGET, vol. 5, 2014, pages 2418 - 2427
TURATO CCANNITO SIMONATO S, G, DTERRIN LFOURTH SBIASIOLO ARUVOLETTO MMARTINI AFASOLATO SZANUS GCILLO U: "SerpinB3 and Yap interplay increases Myc oncogenic activity", SKI REP, vol. 5, 2015, pages 17701
TURATO CKENT PSEBASTIANI GCANNITO STERRIN LBIASIOLO ASIMONATO DWORD MPANTOPOULOS KPONTISSO P: "SerpinB3 is overexpressed in the liver in presence of iron Overload", J INVEST MED, vol. 66, 2018, pages 32 - 38
VIAUD SC THERY PLOIXS, T, V TURSZ LAPIERRELANTZ ZITVOGEL, LN CHAPUT: "Dendritic cell-derived exosomes for cancer immunotherapy: what's next?", CANCER RES, vol. 70, 2010, pages 1281 - 1285, XP055108702, DOI: doi:10.1158/0008-5472.CAN-09-3276

Also Published As

Publication number Publication date
US20220143098A1 (en) 2022-05-12
US12239667B2 (en) 2025-03-04
WO2020165851A1 (en) 2020-08-20
EP3923961A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
IL305753A (en) Extracellular vesicles from stem cells
EP4009989A4 (en) Therapeutic extracellular vesicles
IL286556A (en) Extracellular vesicles for vaccine delivery
IL286260A (en) Plant-derived extracellular vesicle (evs) compositions and uses thereof
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
IL284185A (en) Compositions for drg-specific reduction of transgene expression
SMT202400467T1 (it) Recettori che forniscono una costimolazione mirata per la terapia cellulare adottiva
DK4328309T3 (da) Lipidsammensætning
EP3981435A4 (en) FAT COMPOSITION
IT201900024580A1 (it) Vescicole extracellulari da microalghe
EP3852770A4 (en) SURFACE MODIFIED EXTRACELLULAR VESICLES
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
ITUA20161510A1 (it) Composizione per colorare la fibra cheratinica
BR112015014502A2 (pt) composições para higiene oral contendo haletos de zinco-aminoácidos
IL289543A (en) Antibody compositions for disrupting biofilms
IL291690A (en) Extracellular vesicle assemblies
IT201700118597A1 (it) Composizione per colorare la fibra cheratinica
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
GB201915855D0 (en) An extracellular vesicle
IL281720A (en) Hmgb1 protein derivatives for the removal of biofilms
EP3950060A4 (en) COMPOSITION TO PROMOTE THE SECRETION OF EXTRACELLULAR VESICLES
HUE071452T2 (hu) Szállítórendszer
EP3846308C0 (en) VOLTAGE BALANCING SYSTEM
EP4054527A4 (en) TOPICAL ADMINISTRATION OF TOFACITINIB USING IONIC LIQUID
EP4070457A4 (en) MULTI-CHANNEL MULTIPLEXER